ARNO TRIAL

(<u>Antithrombotic Regimens aNd Outcome</u>)

A RANDOMIZED TRIAL COMPARING BIVALIRUDIN WITH UNFRACTIONED HEPARIN IN PATIENTS UNDERGOING ELECTIVE PCI

David Antoniucci, TCT 2008, Washington DC

ARNO TRIAL

➤The aim of this randomized study is to determine if bivalirudin is still superior to unfractionated heparin plus protamine in patients undergoing elective PCI.

All patients undergoing PCI and pretreated with aspirin (325 mg), and a 600 mg loading dose of clopidogrel at least 6 hours before PCI were considered eligible for enrolment.

TREATMENTS

Aspirin (325 mg) and clopidogrel (600 mg loading) at least 6 hours before PCI in all patients. Abciximab on a provisional basis.

• Heparin group: 100 IU per kg of body weight with or without additional boluses to achieve an ACT of 250 to 300 seconds. Protamine 0.5 mg per 100 IU of heparin utilized.

• Bivalirudin group: bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.


 Immediate post-PCI sheath removal and routine use of closure devices in all patients.

ONE-MONTH OUTCOME -BLEEDING

	Bivalirudin (n=425)	Heparin (n=425)	ρ
Major bleeding			
in-hospital	2 (0.5%)	9 (2.1%)	0.033
one-month	4 (0.9%)	12 (2.8%)	0.043
> 3gr/dL overt source,	n 2	3	
<u>></u> 4gr/dL, n	0	3	
blood transfusion, n	2	6	
➢Minor bleeding	2.4%	2.4%	NS

ONE-MONTH OUTCOME

	Bivalirudin (n = 425)	Heparin (n = 425)	р value
Death/MI/TVR	12 (2.8%)	27 (6.4%)	0.014
Death	1 (0.2%)	6 (1.4%)	0.057
MI	11 (2.4%)	20 (4.5%)	0.098
Q-wave	1	1	
TVR	2 (0.4%)	3 (0.7%)	0.411
NCO	14 (3.3%)	33 (8.0%)	0.004
Definite stent thrombosis 2 (0.5%)		1 (0.3%))
acute	1	0	
subacute	1	1	



CONCLUSIONS

In this randomized trial of patients undergoing elective PCI and pre-treated with aspirin and clopidogrel, <u>bivalirudin</u> compared to unfractionated heparin plus protamine resulted in <u>a significant reduction</u> of major bleeding, of the composite of death, MI, TVR, and in a better net clinical outcome.